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Background: In many European countries, Canada,
and Japan, the nonbenzodiazepine zopiclone is now
among the most frequently prescribed hypnotic drugs.
This ﬁnding can be explained by the growing view
among physicians that zopiclone is more effective and
safer than conventional benzodiazepines. However, in
4 studies using similar procedures, it has been shown
that zopiclone 7.5 mg causes moderate to severe
impairment in driving performance.
Objective: The goal of the present article was to
review these studies and analyze the pooled data to
determine whether the severity of effects is modiﬁed
by the sex and age of the subjects.
Methods: The driving data of the placebo and
zopiclone 7.5 mg evening treatment periods from a
total of 4 studies conducted at Maastricht University
were included in this pooled analysis. All studies were
conducted according to balanced double-blind, cross-
over designs. The effects on driving were always
measured the next morning, between 10 and 11 hours
after administration, by using a standardized highway
driving test. A total of 101 healthy volunteers of both
sexes in equal proportions (with no reports of insom-
nia) participated. Subjects comprised young volunteers
(age range, 21–45 years) in 3 studies and older
volunteers (age range, 55–75 years) in the fourth study.
Results: Results show that zopiclone 7.5 mg has sig-
niﬁcant and clinically relevant performance-impairing
effects on driving in the morning, until 11 hours after
bedtime ingestion. The effects did not differ between
male and female subjects and did not increase with age,
at least until 75 years. The effects of zopiclone 7.5 mg
are comparable to the effects of a mean blood alcohol
concentration between 0.5 and 0.8 mg/mL, which hasJanuary 2014been associated with a 2- to 3-fold increase in the risk
of becoming involved in a trafﬁc accident.
Conclusions: We concluded that patients using an
evening dose of zopiclone 7.5 mg should avoid activity in
skilled work and participation in trafﬁc the morning after
intake. General practitioners’ beliefs regarding the beneﬁ-
cial safety proﬁle of zopiclone may need adjustment, and
patients using zopiclone 7.5 mg should be warned accor-
dingly. There is no need to differentiate warnings about
zopiclone’s residual impairing effects depending on the sex
of the patient. (Clin Ther. 2014;36:141–150) & 2014 The
Authors. Published by Elsevier, Inc.
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effects, zopiclone.
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The prescription of newer hypnotic agents such as
zopiclone, zolpidem, and zaleplon (the so-called Z
drugs) has been steadily rising over the last few years,
while prescriptions of benzodiazepines have been fall-
ing.1 In many European countries, Canada, and Japan,
the nonbenzodiazepine zopiclone is now among the
most frequently prescribed hypnotic drugs.2–6 This
ﬁnding can be explained by the growing view among
physicians that these newer hypnotic agents are more
effective and safer than conventional benzodiazepines.7141
Clinical TherapeuticsA recent survey comparing primary care physicians’
perceptions of beneﬁts and risks of benzodiazepine and
Z-drug use found that Z drugs were believed to be
more effective than benzodiazepines in terms of pa-
tients feeling rested on waking, daytime functioning,
and total sleep time.8 They were also thought to be
safer in terms of tolerance, dependence, residual
daytime sedation, and road trafﬁc accidents.
Regarding the risk of next-morning impairment,
however, there may be age and sex differences. Such
differences became apparent for zolpidem as new
dosage forms were developed.9 Women were found
to clear zolpidem more slowly than men, resulting
occasionally in next-morning blood levels associated
with signiﬁcant driving impairment. Consequently, the
US Food and Drug Administration required revision
to the labels of zolpidem-containing products to
recommend lower dosing, particularly for women. It
may be that sex-speciﬁc labeling revisions will be
required for other insomnia drugs as well, including
zopiclone, after the US Food and Drug Administration
has reviewed all available data.
There is little research into the potential age and
sex differences in next-day effects of zopiclone on
driving. Our group has conducted a number of
experimental studies assessing zopiclone’s residual
effects on driving, but sample sizes and age ranges in
individual studies were too small to analyze age and
sex differences. Four studies,10–13 however, have used
similar designs, with the same driving test and iden-
tical procedures, which justiﬁes aggregating the data
for analysis of age and sex effects across studies. All
studies were conducted according to double-blind,
placebo-controlled crossover designs in healthy male
and female volunteers. Three studies were conducted
in young volunteers10–12 and one in elderly volun-
teers.13 In all studies, single doses of zopiclone 7.5 mg
were administered at bedtime, in the presence of an
investigator, and effects on driving were assessed the
next morning by using the same on-the-road driving
test, between 10 and 11 hours after intake.
The aim of the present article was to analyze the
data from these 4 studies10–13 to determine whether
there are clinically relevant age and sex differences in
the risk of next-day driving impairment after use of
zopiclone 7.5 mg at bedtime. Based on results from
pharmacokinetic and pharmacodynamic studies,14–17
it is expected that impairment effects on driving
increases with age, due to the decreased clearance,142prolonged half-lives, and increased sensitivity found in
elderly subjects. Because no clinically relevant sex
differences in zopiclone kinetics have been reported,
it was not expected that impairment effects would
differ signiﬁcantly between men and women.14,15
MATERIALS AND METHODS
Studies
The driving data of the placebo and zopiclone 7.5
mg evening treatment periods from a total of 4 studies
conducted at Maastricht University were included in
this pooled analysis.10–13 All studies were conducted
according to balanced, double-blind, crossover designs,
including treatment conditions consisting of adminis-
tration of single oral doses of zopiclone 7.5 mg and
placebo at bedtime. The effects on driving were always
measured the next morning, between 10 and 11 hours
after administration, by using a standardized highway
driving test. Subject samples comprised healthy volun-
teers of both sexes in equal proportions, with no reports
of insomnia. Subjects were young volunteers (age range,
21–45 years) in 3 studies and elderly volunteers (age
range, 55–75 years) in 1 study. Table I summarizes the
treatment conditions and characteristics of the subject
samples for each study.
Study 110 was designed to assess the residual effects
of evening and middle-of-the-night doses of zaleplon
10 mg and 20 mg compared with those of zopiclone
7.5 mg and placebo. Subjects included 28 healthy
young volunteers (14 female, 14 male) with a mean
(SD) age of 31.2 (5.7) years.
Study 211 was designed to evaluate the residual
effects of zopiclone 7.5 mg and zaleplon 10 mg
administered at bedtime and to compare them with
the effects of a low dose of alcohol. Thirty healthy
young volunteers (15 female, 15 male) with a mean
age of 31.6 (6.9) years participated in a 2-part cross-
over study. Part 1 was conducted as a single-blind,
2-way crossover design with afternoon administration
of alcohol or alcohol/placebo drinks. Driving perform-
ance was assessed when blood alcohol concentrations
(BACs) were just below the legal limit for driving (ie,
0.5 mg/mL). Part 2 followed a double-blind, 3-way
crossover design. Treatment conditions were zopi-
clone 7.5 mg, zaleplon 10 mg, and placebo adminis-
tered at bedtime.
Study 312 was designed to assess the residual effects
of evening and middle-of-the-night doses of gaboxa-
dol 15 mg compared with those of evening doses ofVolume 36 Number 1
Table I. Summary of the study designs of the 4 studies included in the pooled analysis. All studies were conducted following a double-blind,
crossover design.
Study Treatments Subjects
Age* and
Range (y) Weight* (kg)
Duration of
Driver’s
License (y)*
Annual
Mileage* (km/y) Reference
1 Evening and middle-of-the-night
doses of: zaleplon 10 mg,
zaleplon 20 mg, zopiclone
7.5 mg, and placebo
14 females, 31.2 (5.7); F: 66.1 (6.7) F: 11.1 (5.7) F: 12,686 (4584) Vermeeren
et al10 (1998)14 males 23–40 M: 78.7 (14.6) M: 11.1 (5.1) M: 23,214 (17,660)
2 Evening doses of: zaleplon 10 mg,
zopiclone 7.5 mg, and placebo
15 females, 31.6 (6.9); F: 60.6 (6.1) F: 10.2 (7.0) F: 14,600 (10,614) Vermeeren
et al11 (2002)15 males 21–45 M: 80.2 (10.9) M: 13.3 (6.9) M: 23,800 (21,415)
3 Evening doses of: gaboxadol 15
mg, zopiclone 7.5 mg, and
placebo Middle-of-the-night
doses of: gaboxadol 15 mg,
zolpidem 10 mg, and placebo
12 females 31.4 (7.5); F: 66.8 (6.7) F: 11.2 (8.4) F: 13,167 (13,704) Leufkens
et al12 (2009)13 males 22–44 M: 77.7 (9.3) M: 12.1 (5.6) M: 15,808 (6600)
4 Evening doses of: temazepam 20
mg, zopiclone 7.5 mg, and
placebo
10 females 64.3 (4.3); F: 64.8 (5.6) F: 34.2 (9.9) F: 8258 (4207) Leufkens and
Vermeeren13 (2009)8 males 56–73 M: 77.0 (4.9) M: 43.9 (4.8) M: 11,563 (4640)
F ¼ female; M ¼ male.
*Mean (SD).
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Clinical Therapeuticszopiclone 7.5 mg, middle-of-the-night doses of zolpi-
dem 10 mg, and placebo. A total of 25 healthy young
volunteers (12 female, 13 male; mean age, 31.4 [7.5]
years) completed this 5-way crossover study.
Study 413 was conducted to assess the residual effects
of evening doses of zopiclone 7.5 mg, temazepam 20
mg, and placebo in healthy elderly volunteers. The 18
subjects (10 female, 8 male) were healthy elderly drivers
with a mean age of 64.3 (4.3) years.
Subjects
The complete dataset contained 101 volunteers (51
females, 50 males) in the age range of 21 to 73 years.
Participants needed to possess a valid driving license
for at least 3 years and have a driving experience over
the preceding 3 years of at least 5000 km/year for the
young volunteers and at least 3000 km/year for the
older volunteers.
All subjects were screened by using a medical
history questionnaire, a physical examination includ-
ing ECG, blood chemistry and hematology assess-
ments, and urinary tests for pregnancy and drugs of
abuse. Common exclusion criteria in the studies were
any history or current evidence of any clinically
signiﬁcant physical or mental disorders, alcoholism,
or drug abuse; acute illness; use of systemic medica-
tion except oral contraceptives; use of any psycho-
tropic drug; blood donation or participation in any
other clinical trial within the previous 3 months; and
consumption of 46 beverages containing caffeine per
day, use of410 cigarettes per day, and drinking421
alcohol-containing beverages per week.
All studies were conducted in accordance with the
code of ethics on human experimentation established
by the World Medical Association’s Declaration of
Helsinki (1964) and its subsequent amendments. The
protocols were approved by the medical ethics com-
mittee of Maastricht University and University Hos-
pital of Maastricht. Subjects signed a written informed
consent form before initiation of any study-related
assessments.
Procedure
Subjects were individually trained to perform the
driving test. One week before the ﬁrst treatment
period, subjects slept in the same facilities as during
treatment periods to overcome possible sleep distur-
bances associated with sleeping in an unfamiliar
environment. On the morning after this habituation,144night subjects rehearsed all tests and procedures,
including the driving test.
During treatment periods, zopiclone 7.5 mg and
placebo were orally administered at bedtime. Subjects
were awakened after 8 hours in bed and served a light
breakfast without caffeine. They then underwent a
battery of various psychometric tests to assess driving-
related behavior. The driving test was always con-
ducted between 10 and 11 hours after bedtime
administration.
Highway Driving Test
The driving test used in all studies was developed
and standardized by O’Hanlon18 in the early 1980s. In
this test, the subject operates a specially instrumented
vehicle over a 100-km (61-mile) primary highway
circuit in normal trafﬁc, accompanied by a licensed
driving instructor having access to dual controls. The
subject’s task is to maintain a constant speed of 95 km/
h (58 miles/h) and a steady lateral position between the
delineated boundaries of the slower trafﬁc lane. Test
duration is 1 hour, during which the vehicle’s speed
and lateral position are continuously recorded. These
signals are edited ofﬂine to remove data recorded
during overtaking maneuvers or disturbances caused
by roadway or trafﬁc situations. The remaining data
are then used to calculate means and SDs of lateral
position and speed. The pooled lateral position var-
iance is calculated, and its square root, the mean-
adjusted SD of lateral position (SDLP in centimeters), is
taken as the primary outcome variable. SD of speed
(SDSP in kilometers per hour) is measured as a
secondary outcome variable and is an index of subjects’
ability to maintain a constant speed.
SDLP is an integrated measure of road-tracking
error or “weaving.” It is an extremely reliable index
(test–retest r ¼ 0.70–0.90) of individual driving
performance and has proven sensitive to many sedat-
ing drugs.19–24 The test was calibrated for the effects
of alcohol in a closed circuit study in which 24 social
drinkers were tested sober and after controlled drink-
ing to raise BACs in steps of 0.3 g/L to a maximum of
1.2 g/L.25 In line with the relation between BAC and
accident risk as estimated in a large epidemiologic
study by Borkenstein et al,26 the relation between
BAC and SDLP was shown to be an exponential
function. Based on this relation, BACs of 0.5, 0.8, and
1.0 g/L were associated with mean changes in SDLP of
2.4, 4.2, and 5.1 cm, respectively. Owens andVolume 36 Number 1
T.R.M. Leufkens and A. VermeerenRamaekers27 combined experimental and epidemio-
logic BAC data and found that there is a very high
correlation (r ¼ 0.99) between the increase of SDLP
relative to placebo and the risk of becoming involved
in a trafﬁc accident.
Statistical Analysis
Statistical analyses were performed by using zopi-
clone – placebo difference scores in SDLP and SDSP as
dependent variables (ie, ΔSDLP and ΔSDSP, respec-
tively). ΔSDLP and ΔSDSP were analyzed separately
by using 2-way ANOVAs, with study and sex as ﬁxed
between-subject factors. The signiﬁcant main study
effects were further analyzed by using 6 simple
contrasts between the studies’ change scores in elderly
and young volunteers; the Tukey A correction was
used to adjust for 6 comparisons.
To determine which subject characteristic best
predicted zopiclone’s effect on driving, a step-wise
regression analysis was used, with ΔSDLP as the
dependent variable and sex, age, weight, years of
driving experience, and annual mileage as predictors.
To compare residual effects on SDLP and SDSP,
correlations (Pearson r) and effect sizes (Dunlap’s d28)
were calculated for studies and sexes separately, and
for the total group.
RESULTS
Subjects
There were no signiﬁcant differences between stud-
ies with respect to sex composition, weight, and aver-
age annual mileage of the subjects (Table I). Subjects in
study 4 were older and had, as can be expected, signiﬁ-
cantly more years of driving experience compared with
subjects in the other studies (all, P o 0.001). Overall,
male subjects differed from female subjects in terms of
body size (height and weight, Po 0.001) and in terms
of driving experience. They had more years of driving
experience (P ¼ 0.016) and drove more kilometers per
year (P ¼ 0.015).
Tests Terminated Prematurely
A total of 4 driving tests were terminated prema-
turely due to excessive drowsiness. All 4 tests were
conducted after use of zopiclone. Two tests were
stopped before scheduled completion in study 1: one
by the driving instructor and one at the subject’s
request. The driving instructors also stopped 1 test in
study 2 and 1 test in study 4. SDLP scores for these testsJanuary 2014were calculated from the data collected until termina-
tion and were included in the statistical analyses.
SD of Lateral Position
Figure 1 shows the individual and mean SDLP
scores after administration of placebo and zopiclone
7.5 mg for each study separately.
As reported in the original publications, the mean
increases in SDLP after use of zopiclone compared with
placebo were signiﬁcant in each study, varying from
1.94 cm in study 4 with elderly subjects to 4.88 cm in
study 1 with young subjects. The overall mean (SD)
increase in SDLP after use of zopiclone compared with
placebo was 3.33 (3.42) cm, which is highly signiﬁcant
(F1,93 ¼ 87.96, P o 0.0001). Analysis showed an
overall difference in ΔSDLP between studies (F3,93 ¼
3.69, P ¼ 0.015), which was due to a signiﬁcantly
smaller ΔSDLP in study 4 compared with study 1 (P ¼
0.025). There was no overall difference in ΔSDLP
between male and female subjects (3.16 vs 3.48 cm,
respectively; F o 1) or a sex-by-study interaction.
Regression analysis of ΔSDLP with sex, age,
weight, years of driving, and annual mileage as
independent variables revealed that only age (F1,99 ¼
5.7, P ¼ 0.019) and years of driving (F1,99 ¼ 8.2, P ¼
0.005) predicted ΔSDLP, with a β coefﬁcient of –0.23
and –0.27 and adjusted R2 of 5% and 7%, respec-
tively (Figure 2). Years of driving experience was
highly correlated with age (r ¼ 0.95).
SD of Speed
The ability to keep a constant speed, as measured
by using SDSP, differed signiﬁcantly between placebo
and zopiclone (F1,93 ¼ 17.86, P o 0.0001). Overall,
the variability in speed was increased by 0.17 km/h
after use of zopiclone. Zopiclone’s effects on SDSP did
not differ between studies and sexes (F’s o 1).
Effect Sizes
Table II shows the effect sizes of changes in SDLP
and SDSP for the studies and male and female subjects.
Effect sizes on SDLP were large, with a mean of 0.67
and ranging from 0.50 in study 4 with elderly subjects
to 0.96 in study 1 with young volunteers. The overall
effect size on SDSP (0.35) was smaller than on SDLP,
ranging from 0.30 in study 3 to 0.73 in study 4. Effect
sizes on SDLP were slightly smaller for male subjects
than for female subjects, whereas effect sizes on SDSP
were slightly larger for male than for female subjects.145
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Figure 1. Individual SD of lateral position (SDLP) scores for each study separately, including the mean SDLP.
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The overall correlation between ΔSDLP and ΔSDSP
was 0.41 (Po 0.001), and it ranged between 0.30 (NS)
in study 3 and 0.73 (P o 0.01) in study 4 (Table II).–3
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Figure 2. Regression line and individual changes in SDLP
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146DISCUSSION
The present article was intended to determine age and
sex inﬂuences on residual effects of zopiclone 7.5 mg
on driving performance as measured by using a–3
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Volume 36 Number 1
Table II. Mean (SD) change scores (Δ), effect sizes, and correlations between changes in mean-adjusted SD
of lateral position (SDLP) and SD of speed (SDSP) for each study and sex separately, and overall.
Study
No. of
Subjects
Tests Terminated
Prematurely No. (%)
ΔSDLP*
(cm)
ΔSDLP Effect
Size (Dunlap’s d)
ΔSDSP*
(km/h)
ΔSDSP Effect
size (Dunlap’s d)
Correlation ΔSDLP –
ΔSDSP (Pearson’s r)
By study
Study 1: Vermeeren
et al10 (1998)
28 2 (7.1) 4.88 (4.50) 0.96 0.15 (0.38) 0.35 0.58
Study 2: Vermeeren
et al11 (2002)
30 1 (3.3) 3.38 (2.88) 0.89 0.11 (0.39) 0.24 0.34
Study 3: Leufkens
et al12 (2009)
25 0 2.53 (2.65) 0.82 0.25 (0.30) 0.54 0.30
Study 4: Leufkens and
Vermeeren13 (2009)
18 1 (5.6) 1.94 (2.32) 0.50 0.21 (0.59) 0.37 0.73
By sex
Female 51 3 (5.9) 3.49 (3.27) 0.70 0.16 (0.45) 0.30 0.51
Male 50 1 (2.0) 3.17 (3.59) 0.62 0.19 (0.37) 0.41 0.31
Overall 101 4 (4.0) 3.33 (3.42) 0.67 0.17 (0.41) 0.35 0.41
*Mean (SD).
T.R.M. Leufkens and A. Vermeerenstandardized on-the-road driving test in normal traf-
ﬁc. Data from 101 subjects of 4 separate placebo-
controlled, double-blind crossover studies using the
same procedures were pooled and analyzed to deter-
mine whether zopiclone’s impairment effects depend
on age or sex or on associated differences in weight or
driving experience of the subjects.
Zopiclone impaired subjects’ control over the
vehicle’s lateral position on the road (ie, weaving)
and driving speed. Weaving as measured by using
SDLP increased on average by 3.3 cm, which repre-
sents a moderate to large effect size (Dunlap’s d ¼
0.67). Compared with the effects of alcohol in the
same test,25 a 3.3-cm mean increase in SDLP is
comparable to the effects of a mean BAC between
0.5 and 0.8 mg/mL, which is associated with a 2- to 3-
fold increased risk of becoming involved in a trafﬁc
accident.29 According to the International Council on
Alcohol, Drugs and Trafﬁc Safety, such effects can be
classiﬁed as moderately severe impairment of driving
performance.30
Zopiclone’s effects on variance in driving speed
(SDSP) were also signiﬁcant but considerably less
pronounced compared with those on SDLP in terms
of effect sizes (Dunlap’s d of 0.35 vs 0.67, respectively).
The overall correlation between zopiclone’s effects on
SDLP and SDSP was moderate (r ¼ 0.41). This ﬁnding
supports the idea that these factors measure different
processes and indicates that subjects’ control of theJanuary 2014vehicle’s lateral position is most sensitive to the residual
effects of zopiclone. This ﬁnding is supported by results
from studies by Bocca et al31 and Berthelon et al32,33
using various scenarios in driving simulators for assess-
ing the residual effects of zopiclone 7.5 mg. These
investigators found that zopiclone signiﬁcantly im-
paired control of lateral position but not control of
speed,31 collision anticipation,32 or processing of visual
information in a driving context.33 Moreover, an
epidemiologic study of unsafe driving actions by
crash-involved drivers showed that “failure to stay in
proper lane/running of road” was the most frequently
reported unsafe driving action by benzodiazepine
users.34 This ﬁnding supports the validity of SDLP
for measuring safe driving and its impairment by
sedating drugs such as benzodiazepines.
Importantly, no sex differences were found in the
effects of zopiclone on SDLP and SDSP. This is in
line with ﬁndings from a previous review of effects
of sleep medication, including zopiclone, on driving
performance in men and women separately.35 In that
review, results may have suffered from increased
variance, however, because the data were combined
from 6 experimental studies conducted over a large
time period by different centers and with differences in
design, study population, and setting. Nevertheless,
other studies have found that the subject’s sex does
not seem to have important effects on the kinetics of
zopiclone and other substrates of the cytochrome P-450147
Clinical Therapeutics3A system.17,36 On the one hand, drugs have been
found to produce larger pharmacologic responses in
female subjects than in male subjects,37,38 which can
usually be explained by their lower weight. Conversely,
it has been found that total clearance of drugs metab-
olized by the cytochrome P-450 3A4 system, such as
zopiclone, is slightly faster in women compared with
men, although results were not consistent.16,39,40 The
combination of these effects may explain the lack of sex
differences in the residual effects of zopiclone.
The effects of age were surprising. Contrary to the
expectation that impairment effects would increase
with age, the effect on driving in our older sample was
generally less than that found in the studies with
younger volunteers. The difference was signiﬁcant for
only 1 of 3 studies, however.10 Several factors may
have contributed to this ﬁnding. First, our older
subjects were all younger than 75 years. Only 2
participants were older than 70 years. In addition,
they were selected to be healthy and having normal
liver and kidney function. A study by Gaillot et al15
found that age-related increases of zopiclone’s half-life
were signiﬁcant only in the older subjects (ie, those
aged 475 years). Second, increased drug effects in
elderly subjects may also be due to age-related reduc-
tions in body size and body fat.41 In our studies, there
were no signiﬁcant differences in weight between
subject samples. Finally, our elderly subjects had
signiﬁcantly more years of driving experience and
were still regular drivers. Their driving performance
after placebo administration was generally similar or
even better in terms of SDLP compared with younger
drivers. Nevertheless, both age and driving experience
predicted only 5% to 7% of the variation in effects,
indicating that the relation is weak.
Although the protective effects of age or driving
experience seemed low, the results are supported by
other experimental and epidemiologic studies suggest-
ing that younger and less experienced drivers are more
sensitive to drug effects. A number of epidemiologic
studies have found that risks for trafﬁc accidents
associated with use of benzodiazepines increase most
for young male subjects.22 In addition, a recent on-
the-road driving study found that the effects of low
doses of alcohol on weaving were more severe in
novice drivers than in experienced drivers.42 Novice
drivers are thought to make use of more cognitive
resources than experienced drivers. The sedative
properties of hypnotic agents may inﬂuence more148cognitive skills in relatively inexperienced drivers
and, as a consequence, impair performance to a
larger extent than in experienced drivers. Age-related
increases in driving experience may therefore have
protective effects on drug-induced driving impairment.
It should be noted that the effects shown were found
in medication-naive drivers after single use. Insomnia
patients often use hypnotic agents repeatedly, which
may induce the development of tolerance.43 Tolerance
toward the sedative effects of these agents may result in
less severe driving impairment. Epidemiologic studies
have shown, however, that the relative risk of becoming
involved in a trafﬁc accident is still signiﬁcantly increa-
sed after 1 month of treatment.44 This ﬁnding suggests
that the development of tolerance is limited and will not
be full-scale. In addition, patients today are recom-
mended to use hypnotic agents on an as-needed basis,
hampering the development of tolerance. An inconven-
ient consequence of that recommendation is that
patients are more likely to remain susceptible to the
sedative residual effects of these drugs.
It is important to note that subjects affected by
impairment after taking zopiclone frequently do not
recognize their impaired state. In all 4 studies, subjects
were asked to indicate their subjective alertness in the
morning after evening administration by using a visual
analog scale.45 Subjects reported no differences in
feelings of alertness between placebo and zopiclone
administration. In the study by Vermeeren et al,11
however, subjects were able to detect the impairment
effects of alcohol on their alertness when BAC values
were 0.4 mg/mL. In contrast, the effects on driving
performance after alcohol were less impairing than the
effects of zopiclone 7.5 mg, showing that the subjects’
alertness does not correctly predict their driving
performance. This ﬁnding stresses the importance of
providing clear and comprehensive information by
general practitioners and pharmacists to their patients
about the potentially hazardous effects of zopiclone 7.5
mg on driving performance. It also stresses the need to
consider lowering the dose, not only for elderly subjects
or women, but also for younger patients and men.
Whether the S-enantiomer of zopiclone, eszopi-
clone, is safer with respect to residual effects is
unknown. Assuming dose equivalence with respect
to hypnotic effects and comparing the pharmacoki-
netic proﬁles of both hypnotic agents, there is no
reason to assume that eszopiclone will not have effects
on driving the morning after evening administration.46Volume 36 Number 1
T.R.M. Leufkens and A. VermeerenHowever, to the best of our knowledge, a study
investigating eszopiclone’s residual effects on actual
driving performance has not been conducted.
CONCLUSIONS
The results of the present study found that zopiclone
7.5 mg had signiﬁcant impairment effects on driving
performance at least until 11 hours after hypnotic
agent intake. The effects did not differ between male
and female subjects and did not increase with age, at
least until 75 years. Patients should be warned about
the potential hazards of using zopiclone 7.5 mg when
they have to engage in morning trafﬁc, and they
should be advised to refrain from driving or engaging
in any activity that requires full alertness the morning
after use. There seems to be no need for differentiating
warnings based on sex or age of the user.
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